NNNN
Anbio Biotechnology
4.05
+0.25 (+6.58%)
52w low 3.09
44.73 high
2.3% of range
Financial Analysis
| (USD) | Dec 21 | Dec 22 | Dec 23 | Dec 24 | Dec 25 | Trend |
|---|---|---|---|---|---|---|
| Total Revenue | -- | 23.54M | 6.71M | 8.19M | 8.65M | |
| Cost of Revenue | -- | 10.98M | 3.35M | 2.30M | 1.10M | |
| Gross Profit | -- | 12.56M | 3.36M | 5.89M | 7.54M | |
| Operating Expenses | -- | 2.37M | 1.40M | 3.89M | 1.78M | |
| R&D | -- | 200.00K | 134.70K | 454.23K | 201.31K | |
| SG&A | -- | 2.17M | 1.27M | 3.44M | 1.57M | |
| Operating Income | -- | 10.20M | 1.96M | 2.00M | 5.77M | |
| EBITDA | -- | 10.03M | 1.97M | 2.00M | 5.77M | |
| Pretax Income | -- | 10.01M | 2.25M | 2.37M | 6.40M | |
| Income Tax | -- | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -- | 10.01M | 2.25M | 2.37M | 6.40M | |
| EPS Diluted | 0.03 | 0.07 | 0.01 | 0.05 | -- | |
| Diluted Shares | 100.00M | 143.89M | 187.78M | 43.89M | -- |
Revenue CAGR
-28.4%
Net Income CAGR
-13.8%
EPS CAGR
+28.7%
FCF CAGR
--
Revenue YoY
+5.6%